InvestorsHub Logo
Followers 0
Posts 5
Boards Moderated 0
Alias Born 09/27/2016

Re: Spideyboy post# 10567

Monday, 03/06/2017 2:41:24 PM

Monday, March 06, 2017 2:41:24 PM

Post# of 43762
The study is open-label, not double-blind.

From Cel-Sci website:

Study Summary: A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Global Study of the Effects of Multikine Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity and Soft Palate Versus Standard of Care Only.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News